Cannapharmarx, INC 10-Q quarterly reports

CannaPharmaRx reports increased revenue for Q1 2026, yet faces substantial doubt regarding its ability to continue as a going concern due to persistent liquidity challenges and significant liabilities.

CannaPharmaRx reported a Q3 2025 net loss, severe liquidity constraints, defaults under key agreements, and heavy related-party debt amid efforts to expand EU sales and secure financing.

CannaPharmaRx, Inc. reported a significant working capital deficiency and ongoing defaults on lease and royalty payments, raising substantial doubt about its ability to continue as a going concern.

CannaPharmaRx reports increased revenue driven by European sales, but faces substantial doubt about its ability to continue as a going concern due to significant working capital deficiency and accumulated deficit.

CannaPharmaRX reports its first revenue, but also a net loss and ongoing concerns about its ability to continue as a going concern.

CannaPharmaRX reported a net income of $5.36 million for the quarter ended June 30, 2024, primarily driven by changes in the fair value of derivative liabilities, despite ongoing operational losses and a going concern warning.

CannaPharmaRX reported its first revenue in Q1 2024 but continues to face significant financial challenges, including a substantial working capital deficiency and accumulated deficit.